NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

Price$31.52

Value ScoreF

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-31.61%

Price vs S&P 500 (4W)-18.61%

VGM Score36.14

Market Capitalization$3.68B

All Metrics

Book Value / Share (Quarterly)$5.70

P/TBV (Annual)5.82x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-38.66%

Cash Flow / Share (Quarterly)$0.05

Price vs S&P 500 (YTD)-18.31%

Net Profit Margin (TTM)-942.76%

EPS (TTM)$-1.77

10-Day Avg Trading Volume1.38M

EPS Excl Extra (TTM)$-1.77

EPS (Annual)$-1.72

ROI (Annual)-29.82%

Cash / Share (Quarterly)$5.45

Revenue Growth QoQ (YoY)2.08%

ROA (Last FY)-26.49%

Revenue Growth TTM (YoY)-52.13%

EBITD / Share (TTM)$-1.80

ROE (5Y Avg)-39.32%

Operating Margin (TTM)-953.59%

Cash Flow / Share (Annual)$-1.29

P/B Ratio5.54x

P/B Ratio (Quarterly)5.53x

Net Income / Employee (Annual)$-2,038,200

EV / Revenue (TTM)143.02x

Net Interest Coverage (TTM)-6.44x

ROA (TTM)-27.42%

EPS Incl Extra (Annual)$-1.72

Current Ratio (Annual)7.88x

Quick Ratio (Quarterly)9.58x

3-Month Avg Trading Volume1.07M

52-Week Price Return61.56%

Revenue / Employee (TTM)$225,600

Tangible BV / Share (Quarterly)$5.70

P/S Ratio (Annual)163.75x

Asset Turnover (Annual)0.03x

52-Week High$42.20

EPS Excl Extra (Annual)$-1.72

CapEx CAGR (5Y)89.75%

26-Week Price Return-23.68%

Quick Ratio (Annual)7.70x

13-Week Price Return4.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.76x

Enterprise Value$3.23B

Asset Turnover (TTM)0.03x

Revenue / Employee (Annual)$225,000

Pretax Margin (Annual)-905.74%

Cash / Share (Annual)$5.56

3-Month Return Std Dev61.49%

Net Income / Employee (TTM)$-2,127,300

ROE (Last FY)-29.82%

EPS Basic Excl Extra (Annual)$-1.72

P/FCF (TTM)31.39x

EV / Free Cash Flow (TTM)552.41x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.77

ROI (TTM)-29.80%

P/S Ratio (TTM)163.30x

Revenue / Share (Annual)$0.19

Tangible BV / Share (Annual)$5.97

Price vs S&P 500 (52W)37.19%

Year-to-Date Return-10.15%

5-Day Price Return-0.85%

EPS Normalized (Annual)$-1.72

ROA (5Y Avg)-33.58%

Net Profit Margin (Annual)-905.74%

Month-to-Date Return-6.41%

Cash Flow / Share (TTM)$-0.26

EBITD / Share (Annual)$-1.90

Operating Margin (Annual)-1002.90%

P/CF (TTM)628.38x

ROI (5Y Avg)-39.27%

EPS Basic Excl Extra (TTM)$-1.77

P/TBV (Quarterly)5.54x

P/B Ratio (Annual)5.82x

Pretax Margin (TTM)-942.76%

Book Value / Share (Annual)$5.97

Price vs S&P 500 (13W)-3.68%

Beta0.10x

P/FCF (Annual)462.92x

Revenue / Share (TTM)$0.19

ROE (TTM)-29.80%

52-Week Low$17.63

vGradeF

gGradeD

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.40est. -0.50

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.33

4.32

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares	F	D	B	$31.52
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

NewAmsterdam Pharma is a biopharmaceutical company developing therapies for cardio-metabolic diseases, focusing on patients where current treatments are inadequate or poorly tolerated. The company's lead candidate, obicetrapib, is an oral CETP inhibitor designed to lower LDL cholesterol and address limitations of existing LDL-lowering treatments.